Detalhe da pesquisa
1.
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Br J Haematol
; 204(5): 1811-1815, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38171355
2.
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.
Br J Haematol
; 201(4): 682-689, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36822820
3.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Br J Haematol
; 193(3): 551-555, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32524584
4.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Br J Haematol
; 193(4): 750-760, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650100
5.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910333
6.
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
Br J Haematol
; 191(2): 231-242, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32394450
7.
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Br J Haematol
; 201(1): 162-167, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720464
8.
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
Br J Haematol
; 192(1): e14-e16, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222153
9.
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy.
Br J Haematol
; 190(2): e83-e86, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438482
10.
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Lancet Haematol
; 10(2): e93-e106, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529145
11.
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Hematology
; 27(1): 691-699, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35666686
12.
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.
Hemasphere
; 6(6): e738, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35651713
13.
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.
BMJ Open
; 12(11): e063037, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36396306
14.
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Leuk Lymphoma
; 62(6): 1396-1404, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356703
15.
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
Adv Ther
; 38(2): 1328-1341, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33474705
16.
Risk of relapse of multiple myeloma following kidney transplantation.
Clin Kidney J
; 12(2): 216-223, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30976399
17.
Challenges in designing and running smouldering myeloma interventional clinical trials.
EJHaem
; 5(2): 418-420, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38633110
18.
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Blood Cancer J
; 12(9): 128, 2022 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36064540